HOLX Stock Recent News
HOLX LATEST HEADLINES
Hologic, Inc. (NASDAQ:HOLX ) Q2 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Mike Watts - Corporate VP, IR Steve MacMillan - Chairman, President & CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Anthony Petrone - Mizuho Group Lu Li - UBS Casey Woodring - JP Morgan Conor McNamara - RBC Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Operator Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call.
Medical equipment maker Hologic lowered its fiscal 2025 profit forecast, citing uncertainty around the tariffs imposed by U.S. President Donald Trump's administration, sending the company's shares down 3% after the bell on Thursday.
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.03 per share a year ago.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2025.
The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Cellulite Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering. The Global Cellulite Treatment Market was valued at USD 1.57 billion in 2024 and is expected to reach USD 2.47 billion by 2030 with a CAGR of 7.84% during the forecast period. The global cellulite treatment market is a dynamic and rapidly growing segment within the broader healthcare and wellness industry.